Shanghai Henlius Biotech, Inc. (HKG:2696)

Market Cap	37.50B +230.1%
Revenue (ttm)	6.35B +2.8%
Net Income	903.25M +19.1%
EPS	1.66 +19.4%
Shares Out	543.49M
PE Ratio	41.52
Forward PE	40.02
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,273,200
Average Volume	1,368,031
Open	64.75
Previous Close	64.75
Day's Range	64.70 - 69.35
52-Week Range	23.00 - 92.00
Beta	0.59
RSI	47.27
Earnings Date	Mar 20, 2026

About Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn’s diseas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 3,537
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2696

Financial Performance

In 2024, Shanghai Henlius Biotech's revenue was 5.72 billion, an increase of 6.11% compared to the previous year's 5.39 billion. Earnings were 820.47 million, an increase of 50.26%.

Financial numbers in CNY